AL-Mhanna SB, Batrakoulis A, Wan Ghazali WS, et al. Effects of combined aerobic and resistance training on glycemic control, blood pressure, inflammation, cardiorespiratory fitness and quality of life in patients with type 2 diabetes and overweight/obesity: a systematic review and meta-analysis. PeerJ. 2024;12:e17525. https://doi.org/10.7717/peerj.17525.

Article  PubMed  PubMed Central  Google Scholar 

Tan B, Pan XH, Chew HSJ, et al. Efficacy and safety of Tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J Obes. 2023;47(8):677–85. https://doi.org/10.1038/s41366-023-01321-5.

Article  CAS  Google Scholar 

Qin W, Yang J, Ni Y, et al. Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: an updated systematic review and meta-analysis including the latest SURMOUNT-2 trial. Endocrine. 2024;86(1):70–84. https://doi.org/10.1007/s12020-024-03896-z.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ciardullo S, Morieri ML, Daniele G, et al. GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes. Acta Diabetol. 2024;61(8):941–50. https://doi.org/10.1007/s00592-024-02300-6.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16. https://doi.org/10.1056/NEJMoa2206038.

Article  PubMed  CAS  Google Scholar 

Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180–93. https://doi.org/10.1016/S0140-6736(18)32260-8.

Article  PubMed  CAS  Google Scholar 

Chin YH, Ng CH, Chew NW, et al. The placebo response rate and nocebo events in obesity pharmacological trials. A systematic review and meta-analysis. eClinicalMedicine. 2022;54:101685. https://doi.org/10.1016/j.eclinm.2022.101685.

Article  PubMed  PubMed Central  Google Scholar 

Reimann F, Diakogiannaki E, Hodge D, Gribble FM. Cellular mechanisms governing glucose-dependent insulinotropic polypeptide secretion. Peptides. 2020;125:170206. https://doi.org/10.1016/j.peptides.2019.170206.

Article  PubMed  CAS  Google Scholar 

Van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63(12):4186–96. https://doi.org/10.2337/db14-0849.

Article  PubMed  CAS  Google Scholar 

Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig. 2010;1(1–2):8–23. https://doi.org/10.1111/j.2040-1124.2010.00022.x.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Campbell JE. Targeting the GIPR for obesity: to agonize or antagonize? Potential mechanisms. Mol Metab. 2021;46:101139. https://doi.org/10.1016/j.molmet.2020.101139.

Article  PubMed  CAS  Google Scholar 

Zaffina I, Pelle MC, Armentaro G, et al. Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity. Front Endocrinol. 2023;14:1095753. https://doi.org/10.3389/fendo.2023.1095753.

Article  Google Scholar 

Detka J, Głombik K. Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression. Pharmacol Rep. 2021;73(4):1020–32. https://doi.org/10.1007/s43440-021-00274-8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. eClinicalMedicine. 2024;75:102782. https://doi.org/10.1016/j.eclinm.2024.102782.

Article  PubMed  PubMed Central  Google Scholar 

Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–56. https://doi.org/10.1016/j.cmet.2018.03.001.

Article  PubMed  CAS  Google Scholar 

Egan JM. Physiological Integration of Taste and Metabolism. Longo DL, ed. N Engl J Med. 2024;390(18):1699–1710. https://doi.org/10.1056/NEJMra2304578

Bucinskaite V, Tolessa T, Pedersen J, et al. Receptor-mediated activation of gastric vagal afferents by glucagon‐like peptide‐1 in the rat. Neurogastroenterol Motil. 2009;21(9):978. https://doi.org/10.1111/j.1365-2982.2009.01317.x.

Article  PubMed  CAS  Google Scholar 

Smith NK, Hackett TA, Galli A, Flynn CR. GLP-1: molecular mechanisms and outcomes of a complex signaling system. Neurochem Int. 2019;128:94–105. https://doi.org/10.1016/j.neuint.2019.04.010.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol-Regul Integr Comp Physiol. 2016;310(10):R885–95. https://doi.org/10.1152/ajpregu.00520.2015.

Article  PubMed  PubMed Central  Google Scholar 

Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S. Distribution and characterisation of glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab. 2015;4(10):718–31. https://doi.org/10.1016/j.molmet.2015.07.008.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Larsen PJ, Holst JJ. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept. 2005;128(2):97–107. https://doi.org/10.1016/j.regpep.2004.08.026.

Article  PubMed  CAS  Google Scholar 

Hayes MR, Schmidt HD. GLP-1 influences food and drug reward. Curr Opin Behav Sci. 2016;9:66–70. https://doi.org/10.1016/j.cobeha.2016.02.005.

Article  PubMed  PubMed Central  Google Scholar 

Hernandez NS, Weir VR, Ragnini K, et al. GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA. Mol Psychiatry. 2021;26(8):4394–408. https://doi.org/10.1038/s41380-020-00957-3.

Article  PubMed  CAS  Google Scholar 

Thomsen M, Holst JJ, Molander A, Linnet K, Ptito M, Fink-Jensen A. Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring Vervet monkeys. Psychopharmacology. 2019;236(2):603–11. https://doi.org/10.1007/s00213-018-5089-z.

Article  PubMed  CAS  Google Scholar 

Hernandez NS, Schmidt HD. Central GLP-1 receptors: novel molecular targets for cocaine use disorder. Physiol Behav. 2019;206:93–105. https://doi.org/10.1016/j.physbeh.2019.03.026.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes. 2003;27(3):313–8. https://doi.org/10.1038/sj.ijo.0802206.

Article  CAS  Google Scholar 

Hunter K, Hölscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13(1):33. https://doi.org/10.1186/1471-2202-13-33.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Christensen M, Sparre-Ulrich AH, Hartmann B, et al. Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. Int J Obes. 2015;39(11):1651–4. https://doi.org/10.1038/ijo.2015.136.

Article  CAS